Palbociclib Rechallenge for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.
Joan AlbanellJosé Manuel Peréz-GarcíaJuan Miguel Gil-GilCurigliano GiuseppeManuel Ruiz BorregoLaura ComermaJoan GibertMeritxell Bellet-EzquerraBegoña BermejoLourdes Calvo MartinezJuan R De la Haba-RodríguezEnrique EspinosaAlessandro Marco Marco MinisiniVanesa QuirogaAna Santaballa BertranLeonardo MinaBeatriz BellosilloFederico RojoSilvia MenéndezMiguel SampayoRamona Mihaela PopaAndrea MalfettoneJavier CortesAntonio LlombartPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Maintaining palbociclib after progression on prior palbociclib-based regimen seems to be a reasonable, investigational approach for selected patients. A composite biomarker signature predicts a subset of patients who may not derive a greater benefit from palbociclib rechallenge, warranting further validation in larger randomized controlled trials.
Keyphrases
- phase ii
- epidermal growth factor receptor
- clinical trial
- metastatic breast cancer
- open label
- end stage renal disease
- randomized controlled trial
- phase iii
- tyrosine kinase
- ejection fraction
- chronic kidney disease
- advanced non small cell lung cancer
- endothelial cells
- newly diagnosed
- peritoneal dialysis
- study protocol
- double blind
- prognostic factors
- young adults
- pluripotent stem cells